ON4.F ONO PHARMACEUT.

Healthcare Pharmaceuticals Frankfurt Exchange
13.41 EUR
Close of Nov 12, 2026
10.52 14.00
Market cap
EUR 6.30B
P/E
15.4x
P/B
1.25x
ROE
10.3%
Dividend yield
3.45%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Sep 2026.

Is ON4.F undervalued?

Graham number
Price13.41
Graham value14.52
Discount7.6%

ON4.F trades 7.6% below its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

ONO PHARMACEUT. fundamental analysis

No fundamental analysis for ONO PHARMACEUT. yet.

ONO PHARMACEUT. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About ONO PHARMACEUT.

Ono Pharmaceutical Co., Ltd. produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo intravenous infusion and Kyprolis intravenous injection for malignant tumors; Emend capsule intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; Mektovi, Velexbru, and Braftovi capsules for malignant tumors; and ADLUMIZ tablets for cancer cachexia. The company also p…

Full company profile